Introduction
Hyperphosphatemia is one of the most important risk factors for cardiovascular disease and death in maintenance hemodialysis patients (1, 2 (3, 4) .
Because most uric acid is excreted from the kidney, hyperuricemia is usually seen in renal insufficiency patients and maintenance hemodialysis patients. Allopurinol, a xanthine oxidase inhibitor, is used for the treatment of hyperuricemia in patients with reduced GFR. Allopurinol can gen-erally be used safely in chronic kidney disease, although dose adjustments are required due to impaired clearance of oxypurinol, the major active metabolite of allopurinol (5 i g u r e 1 . Co r r e l a t i o n b e t we e n s e r u m u r a t e b e f o r e s e v e l a me r t r e a t me n t a n d t h e c h a n g e i n u r a t e ( 6 mo n t h s a f t e r s e v e l a me r t r e a t me n t ) . 
F i g u r e 2 . E f f e c t o f s e v e l a me r o n s e r u m u r a t e . Ho r i z o n t a l a x i s i n d i c a t e s t h e mo n t h s a f t e r s e v e l a me r t r e a t me n t . * d e n o t e s p = 0 . 0 3 5 5 v s p r e t r e a t me n t ( 0 M) . * * d e n o t e s p = 0 . 0 1 5 2 v s p r e t r e a t me n t ( 0 M) .

Discussion
From the results of large-scale clinical studies, hyperuricemia seems to be one of the risk factors for cardiovascular disease especially in hypertensive patients (8-10). In the
F i g u r e 3 . Co r r e l a t i o n b e t we e n t h e c h a n g e i n u r a t e a n d t h e c h a n g e s i n p h o s p h a t e , c a l c i u m × p h o s p h a t e p r o d u c t , a n d c a l c i u m ( 6 mo n t h s a f t e r s e v e l a me r t r e a t me n t ) .
F i g u r e 4 . Ur a t e a d s o r p t i o n b y s e v e l a me r . AS T -1 2 0 wa s u s e d a s a c o n t r o l a d s o r b e n t .
Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study, it was found that nearly one-third of the protective effect of losartan against cardiovascular disease is derived from the urate-lowering effect of losartan (11). An anti-hyperuricemia measure becomes important in renal in
